Estimates Revisions AN2 Therapeutics, Inc.
Stocks
ANTX
US0373261058
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.890 USD | -2.20% |
|
+4.71% | +328.95% |
| 07-20 | Guggenheim Initiates AN2 Therapeutics at Buy With $9 Price Target | MT |
| 06-29 | AN2 Therapeutics, Inc.(NasdaqGS:ANTX) added to Russell 2000 Index | CI |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | - | - | ||
| ||||
| ||||
| ||||
| ||||
| ||||
| - | |||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Cash or Net Debt
- Stock Market
- Stocks
- ANTX Stock
- Consensus AN2 Therapeutics, Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
